Biconomy Price Surges 75% as Yield Products Launch on Aster and AlphaX DEX

• Biconomy (BICO) surged 75% following the listing of perpetual futures on Aster DEX and AlphaX DEX, triggering liquidated $1.35 million in shorts.
• The Linux Foundation established the Tokenomics Foundation to standardize AI costs measurement.
• Biocon Biologics launched Yesafili in the U.S. as a biosimilar to Regeneron’s Eylea, leveraging its global manufacturing footprint to enter the competitive ophthalmology sector.

Biconomy, a decentralized infrastructure protocol, posted a sharp daily gain of 75.3%, trading at approximately $0.0507. This aggressive move was primarily driven by the introduction of new perpetual futures contracts on two decentralized exchanges within a 24-hour window. Aster DEX listed BICO perps with up to 5x leverage on August 4, followed by AlphaX DEX listing the token with up to 50x leverage and zero fees on August 5.

This concentrated influx of leverage products attracted significant speculative capital, resulting in a short squeeze that wiped out $1.35 million in short positions out of $1.70 million in total liquidations. The move is largely driven by derivatives demand rather than spot buying, highlighting the speculative nature of the recent price action.

Technically, the token broke out of a multi-week consolidation zone near $0.03, with immediate resistance identified at $0.0669. However, the daily Relative Strength Index (RSI) spiked to 91.38, signaling extreme overbought conditions that historically precede pullbacks, even within broader uptrends.

The weekly chart shows the price poking above a descending channel for the first time since mid-2025, though confirmation requires a weekly close above this boundary. Structural risks remain elevated due to high whale concentration, with on-chain data revealing that the top 100 wallets hold 96.6% of the supply.

Just 42 addresses control 91.65% of the market cap, and a Gini score of 0.9961 indicates near-maximum concentration. Significant portions of the circulating supply are held on exchange hot wallets, suggesting potential sell-side pressure in a high-risk environment.

Beyond market volatility, Biconomy is expanding its utility through updated USDG Earn products launched in collaboration with Global Dollar. These products provide users with flexible and fixed-term yield options for staking USDG stablecoins, offering annualized rates from 2.13% to 4.83% depending on lock-up periods.

The flexible product offers an initial 17% APR for five days before adjusting to 2.13% APR, while fixed-term products provide 3.81% APR for a 180-day lock and 4.83% APR for a 360-day lock. Participation is subject to strict deposit limits, with a minimum of 10 USDG and a maximum of 2,000 USDG per user, alongside overall product caps.

Interest is calculated and paid out on the business day following deposit, with early redemption resulting in the forfeiture of all accrued interest. Biconomy reserves the right to adjust rates and limits based on market conditions, with the offering set to commence on May 30, 2026.

How Will the Tokenomics Foundation Impact AI Economics?

The Linux Foundation has launched the Tokenomics Foundation, an initiative designed to define the economics and return on investment (ROI) of artificial intelligence. The organization addresses critical challenges for practitioners, specifically determining the true cost of AI and measuring the value of intelligence generated.

While token usage is a consistent atomic unit of consumption, the foundation acknowledges that total AI costs extend far beyond tokens to include compute, storage, database, cache, and human engineering labor. The foundation’s inaugural Governing Board convened on July 30, with the Technical Steering Committee soon to align on key challenge areas.

The roadmap includes establishing standard terminology for token value, density, input, output, reasoning, and cache. It also aims to create a comprehensive model for the full cost of AI, positioning tokens as one component of the total bill rather than the whole.

Further deliverables involve developing a standard method to measure the total cost of ownership expressed as cost per call, mapping directly to work performed. A framework will also relate AI spend to business outcomes, such as the share of work completed without human involvement compared to current process costs.

What Drives Biocon’s Expansion into the U.S. Biosimilar Market?

Biocon Biologics announced the U.S. commercial launch of Yesafili, a biosimilar to Regeneron’s Eylea 2 mg. The company operates in over 120 countries with seven manufacturing sites, three R&D sites, and a workforce of more than 9,500 employees.

The launch represents a strategic expansion into the U.S. biosimilar market, supported by Biocon's established global operational footprint and regulatory compliance. Biocon has been included in the S&P Global Sustainability Yearbook 2026 for the fourth consecutive year, highlighting its commitment to sustainable growth.

This expansion leverages its global manufacturing and R&D infrastructure to enter the competitive ophthalmology market. The press release includes standard forward-looking statements regarding future expectations, market conditions, and potential risks associated with currency fluctuations, competition, and regulatory changes in the pharmaceutical industry.

Meanwhile, Asante reported current Measured and Indicated Resources of 4.6 million ounces and 1.8 million ounces of Inferred Resources as of December 31, 2025, maintaining levels despite recent production. The company budgets US$23.4 million for exploration in 2026, focusing on infrastructure upgrades to boost throughput and recovery.

At the Bibiani mine, operations are transitioning to higher-grade northern sections of the Main Pit, driving increased plant head grade in the second half of 2026. Significant investments in processing infrastructure, including replacement electric crushing systems, a pebble crusher, and gravity circuit upgrades, are nearing completion.

In the broader corporate landscape, US companies are experiencing a significant rise in cyberattacks spanning healthcare, leisure, and consumer goods. Incidents typically involve social engineering, ransomware, or unauthorized system access, leading to data theft and operational disruptions.

Key incidents include a cyberattack on West Pharmaceutical Services that disrupted global manufacturing and logistics, and a breach at Coca-Cola’s fairlife brand that suspended US production operations. Levi Strauss reported unauthorized access to corporate information, noting no material impact on operations.

The healthcare and education sectors have been particularly vulnerable, with Instructure suffering a hack exposing student data from nearly 9,000 institutions. Novo Nordisk reported unauthorized copying of limited clinical trial patient data, leading to a temporary shutdown of certain internal systems.

These incidents underscore the increasing sophistication of threat actors and the persistent operational risks posed by cybersecurity failures, even when direct financial impacts are deemed non-material.